Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Robin, M; Giannotti, F; Deconinck, E; Mohty, M; Michallet, M; Sanz, G; Chevallier, P; Cahn, JY; Legrand, F; Rovira, M; Passweg, J; Sierra, J; Nguyen, S; Maillard, N; Yakoub-Agha, I; Linkesch, W; Cannell, P; Marcatti, M; Bay, JO; Chalandon, Y; Kröger, N; Gluckman, E; Rocha, V; Olavarria, E; Ruggeri, A; Eurocord and Chronic Malignancies Working Party-European Group for Blood and Marrow Transplantation (CMWP-EBMT).
Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis.
Biol Blood Marrow Transplant. 2014; 20(11):1841-1846 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Linkesch Werner
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%, P = .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results. Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Cord Blood Stem Cell Transplantation - adverse effects
Cord Blood Stem Cell Transplantation - methods
Female -
Fetal Blood -
Hematopoietic Stem Cell Transplantation - methods
Humans -
Male -
Middle Aged -
Primary Myelofibrosis - therapy
Transplantation Conditioning - methods
Treatment Outcome -
Unrelated Donors -

Find related publications in this database (Keywords)
Myelofibrosis
Umbilical cord blood transplantation
© Meduni Graz Impressum